Biofrontera AG

B8F

DE0006046113

Pharmaceuticals

Delayed Xetra Other stock markets 11:24:08 2024-04-19 am EDT			5-day change	1st Jan Change
0.3 ^EUR	-7.98%		-11.76%	-25.19%

Mar. 11	Biofrontera Files Prospectus for Potential Secondary Stock Offerings	MT
Mar. 05	Medicus Pharma Names COO	MT

Biofrontera AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

December 31, 2018 at 05:05 am EST

DGAP Total Voting Rights Announcement: Biofrontera AG / Total Voting Rights Announcement
Biofrontera AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

31.12.2018 / 11:00
Total Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Publication of total number of voting rights

1. Details of issuer

Biofrontera AG
Hemmelrather Weg 201
51377 Leverkusen
Germany

2. Type of capital measure

	Type of capital measure	Date of status / date of effect
X	Conditional capital increase (Sec. 41 para. 2 WpHG)	31.12.2018
	Other capital measure (Sec. 41 para. 1 WpHG)

3. New total number of voting rights:

44632674

31.12.2018 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:	English
Company:	Biofrontera AG
	Hemmelrather Weg 201
	51377 Leverkusen
	Germany
Internet:	www.biofrontera.com


End of News	DGAP News Service

758845 31.12.2018

Latest news about Biofrontera AG

Biofrontera Files Prospectus for Potential Secondary Stock Offerings	Mar. 11	MT
Medicus Pharma Names COO	Mar. 05	MT
Biofrontera AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 28	CI
Earnings Flash (BFRI) BIOFRONTERA Reports Q3 Revenue $8.9M, vs. Street Est of $8.4M	Nov. 09	MT
Biofrontera Licensor Gets FDA Approval for New Formulation of Ameluz to Treat Actinic Keratosis	23-10-10	MT
Biofrontera Says Sun Pharmaceutical Alleging Breach of Contract In Lawsuit	23-10-03	DJ
Biofrontera AG Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-31	CI
Biofrontera Says Skin Disease Therapy Was Well-Tolerated in Phase 1 Safety Trial	23-08-28	MT
Earnings Flash (BFRI) BIOFRONTERA Reports Q2 Revenue $5.8M	23-08-11	MT
Biofrontera Completes Patient Enrollment in Skin Cancer Treatment Study	23-08-10	MT
Top Premarket Decliners	23-07-21	MT
Biofrontera Launches Novel Belixos Active Care	23-07-05	CI
Biofrontera to Effect 1-for-20 Reverse Stock Split	23-07-03	MT
Wall Street Set to Open Lower; Housing Starts Rise More Than Expected	23-06-20	MT
Transcript : Biofrontera AG, Q1 2023 Earnings Call, May 31, 2023	23-05-31
Biofrontera AG Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-31	CI
Biofrontera AG Completes Patient Recruitment of Ameluz Phase I Trial	23-05-17	CI
Biofrontera Says it Obtained US Patent for New Photodynamic Therapy Protocol	23-05-15	MT
Earnings Flash (BFRI) BIOFRONTERA Reports Q1 Revenue $8.7M, vs. Street Est of $9.2M	23-05-12	MT
Biofrontera Enters $6.5 Million Line of Credit With MidCap Business Credit	23-05-11	MT
Biofrontera AG Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-28	CI
Biofrontera Reports Completion of Last Patient Visit in Phase 1 Study to Treat Actinic Keratosis	23-04-26	MT
Biofrontera to Grow Salesforce 'Meaningfully' in 2023	23-03-27	MT
Biofrontera Doses First Patient in Phase 3 Actinic Keratosis Clinical Trial	23-01-09	MT
Biofrontera AG Announces Executive Appointments to Biofrontera UK Ltd	22-12-08	CI

Chart Biofrontera AG

Duration

Period

More charts

Company Profile

Biofrontera AG is a Germany-based biopharmaceutical company. The Company develops drugs and medicinal cosmetics for the treatment of skin diseases and regenerative care of damaged skin. Its portfolio includes: Ameluz, for photodynamic therapy (PDT) of actinic keratoses, and under development for other types of skin cancer and warts; PDT lamp BF-RhodoLED, used after the Ameluz treatment to eliminate infected cells; and Belixos, a dermatological cream with herbal ingredients for the care of itching, inflamed and flaky skin and conditions such as insect bites, burns, neurodermatitis and psoriasis. The Company is also engaged in clinical development of two drug candidates: BF-derm1, a tablet with inhibitor blocking the synthesis of histamine in cells, a cause of allergic reactions; and BF1, a selective serotonin receptor to prevent migraines. The Company operates five wholly owned subsidiaries, notably Biofrontera Inc in the United States. Its main shareholder is MM Familien KG.

Sector

Pharmaceuticals

Calendar

2024-04-24 - Q4 2023 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BIOFRONTERA AG	-25.19%	22.18M
ELI LILLY AND COMPANY	+25.51%	672B
NOVO NORDISK A/S	+24.08%	550B
JOHNSON & JOHNSON	-6.54%	351B
MERCK & CO., INC.	+14.81%	317B
ABBVIE INC.	+6.79%	292B
ASTRAZENECA PLC	+3.19%	211B
NOVARTIS AG	+0.53%	203B
PFIZER, INC.	-10.49%	144B
AMGEN INC.	-7.95%	141B

Other Pharmaceuticals

Biofrontera AG

Equities

B8F

DE0006046113

Pharmaceuticals

Biofrontera AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Latest news about Biofrontera AG

Chart Biofrontera AG

Company Profile

Income Statement Evolution

Quarterly revenue - Rate of surprise

Sector Other Pharmaceuticals